O uso de métodos contracetivos de emergência em estudantes do ensino superior

Os métodos contracetivos apresentam dois objetivos principais: prevenir a gravidez e em alguns casos evitar a transmissão de Doenças Sexualmente Transmissíveis (DST ́s). Atualmente existe uma grande diversidade de métodos contracetivos, para ambos os sexos, no entanto a utilização de qualquer um deles exige uma decisão consciente e responsável. A contraceção de emergência refere - se aos métodos que podem ser utiliza- dos para evitar a gravidez, como resultado de uma relação sexual desprote- gida, falha no método contracetivo ou em caso de violaçã

Comparison of blood neoangiogenesis and lymphatic vascularization in colorectal adenomas from patients with and without concomitant colorectal cancer

Blood and lymphatic vessel proliferation is essential for tumor growth and progression. Most colorectal carcinomas develop from adenomas (adenoma-carcinoma sequence) in a process due to accumulation of molecular genetic alterations. About 5% of adenomatous polyps are expected to become malignant, but data on the differential angiogenic patterns of these lesions in patients with and without concomitant cancer are missing. The aim of the present study is to compare the angiogenic and lymphatic patterns of adenomatous polyps from patients with and without sporadic cancer. Thirty adenomatous polyps (15 from patients with another principal malignant lesion, and 15 from patients without cancer) were submitted to immunohistochemical staining for CD105 (marker for neoangiogenesis) and D2-40 (marker for lymphatic endothelium). Microvessel density and total vascular area were determined by computer image analysis to quantify the immunostained and total areas, and to assess the number of microvessels. Adenomas from patients with carcinoma showed significantly higher values of total vascular area determined by immunostaining for CD105 (cutoff value = 4386 µm²; P = 0.019) and of lymphatic microvessel density determined by immunostaining with D2-40 (cutoff value = 11.5; P = 0.041) when compared with those from patients without cancer. The present data indicate a significant increase in blood microvascular area and in lymphatic microvascular counts in adenomas removed from patients with cancer.59359

Intracerebral Granulocytic Sarcoma In Recurrence Of Chronic Myeloid Leukemia [sarcoma Granulocítico Cerebral Na Recorrência De Leucemia Mielóide Crônica]

[No abstract available]73168Audouin, J., Comperat, E., Le Tourneau, A., Camilleri-Broët, S., Adida, C., Molina, T., Myeloid sarcoma: Clinical and morphologic criteria useful for diagnosis (2003) Int J Surg Pathol, 11 (4), pp. 271-282. , http://dx.doi.org/10.1177/106689690301100404Suzer, T., Colakoglu, N., Cirak, B., Keskin, A., Coskun, E., Tahta, K., Intracerebellar granulocytic sarcoma complicating acute myelogenous leukemia: A case report and review of the literature (2004) J Clin Neurosci., 11 (8), pp. 914-917. , http://dx.doi.org/10.1016/j.jocn.2003.12.018Lee, S.H., Park, J., Hwang, S.K., Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: A case report (2006) J Neurooncol., 80 (1), pp. 101-104. , http://dx.doi.org/10.1007/s11060-006-9163-

Camptothecins Compared With Etoposide In Combination With Platinum Analog In Extensive Stage Small Cell Lung Cancer: Systematic Review With Meta-analysis

Superiority of camptothecin regimens over etoposide-both combined with platinum analogs-in extensive disease small cell lung cancer has been a matter of debate with contradictory findings in randomized trials. A systematic review was sought to elucidate this issue. Methods: Randomized controlled trials comparing first-line camptothecin-platinum doublets versus etoposide-platinum doublets in patients with extensive disease small cell lung cancer were searched in MEDLINE, EMBASE, LILACS, and CENTRAL databases, European Society of Medical Oncology, American Society of Clinical Oncology, and International Association for the Study of Lung Cancer meeting sites. Meta-analyses were performed using fixed-effects model. Subgroup analyses were undertaken comparing each type of camptothecin to etoposide-based regimens. The outcomes of interest were overall survival (OS), progression-free survival (PFS), response rate (RR), and toxicities. Results: Eight studies (3086 patients) were included. The meta-analysis of topotecan regimens (TP) was not reliable due to impending heterogeneity. Meta-analysis of trials testing irinotecan combinations (IP) versus etoposide regimens (EP; 1561 patients) stated an OS improvement in favor of IP arm, though with considerable heterogeneity, whose origin seemed to be a Japanese trial. In the analyses without that study (1407 patients left), IP brought a significant improvement in OS (hazard ratio = 0.87; 95% confidence interval 0.78-0.97; p = 0.02; I 2 = 0). IP also increased PFS (hazard ratio = 0.83; 95% confidence interval 0.73-0.95; p = 0.006; I 2 = 0%). There was no impact in RR (absolute RR 56% with IP; 53% with EP; p = 0.17). IP caused more diarrhea (p < 0.0001) but less hematological toxicities (p < 0.001) than EP. Conclusions: The present meta-analysis demonstrates statistically significant OS and PFS benefits of IP over EP regimens in western and eastern patients. Specific characteristics of safety profile should be taken into account when administrating IP chemotherapy. Copyright © 2010 by the International Association for the Study of Lung Cancer.51219861993Parkin, D.M., Bray, F., Ferlay, J., Global cancer statistics 2002 (2005) CA Cancer J. Clin., 55, pp. 74-108Lara Jr., P.N., Natale, R., Crowley, J., Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124 (2009) J. Clin. Oncol., 27, pp. 2530-2535Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E.L., Piccirillo, J., Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database (2006) Journal of Clinical Oncology, 24 (28), pp. 4539-4544. , DOI 10.1200/JCO.2005.04.4859Lorigan, P., Woll, P.J., O'Brien, M.E.R., Ashcroft, L.F., Sampson, M.R., Thatcher, N., Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer (2005) Journal of the National Cancer Institute, 97 (9), pp. 666-674. , DOI 10.1093/jnci/dji114Chute, J.P., Chen, T., Feigal, E., Simon, R., Johnson, B.E., Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress (1999) Journal of Clinical Oncology, 17 (6), pp. 1794-1801Jones, D., Klementich, V.F.L.R., Phase II trial of Docetaxel and carboplatin in patients with newly diagnosed extensive-stage small cell carcinoma of the lung SCLC (2005) J. Clin. Oncol., 23. , Abstract 7346Gridelli, C., Perrone, F., Ianniello, G.P., Brancaccio, L., Iaffaioli, R.V., Curcio, C., D'Aprile, M., Bianco, A.R., Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: A phase II study (1998) Journal of Clinical Oncology, 16 (4), pp. 1414-1419Dimitroulis, J., Rapti, A., Stathopoulos, G.P., Comparison of cisplatinpaclitaxel combination versus cisplatin-etoposide in patients with smallcell lung cancer: A phase III study (2008) Oncol. Rep., 20, pp. 879-884Mavroudis, D., Papadakis, E., Veslemes, M., Tsiafaki, X., Stavrakakis, J., Kouroussis, C., Kakolyris, S., Georgoulias, V., A multicenter randomized clinical trial comparing paclitaxel-cisplatin- etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer (2001) Annals of Oncology, 12 (4), pp. 463-470. , DOI 10.1023/A:1011131303391Niell, H.B., Herndon II, J.E., Miller, A.A., Watson, D.M., Sandler, A.B., Kelly, K., Marks, R.S., Green, M.R., Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732 (2005) Journal of Clinical Oncology, 23 (16), pp. 3752-3759. , DOI 10.1200/JCO.2005.09.071Socinski, M.A., Smit, E.F., Lorigan, P., Phase III study of pemetrexed plus carboplatin PC versus etoposide plus carboplatin EC in chemonaive patients pts with extensive-stage disease small cell lung cancer ED-SCLC: Interim results (2008) ASCO Meeting Category Lung Cancer Local-Regional and Adjuvant Therapy Abs NSANegoro, S., Fukuoka, M., Niitani, H., A phase II study of CPT-11 a camptothecin derivative in patients with primary lung cancer CPT-11 cooperative study group (1991) Gan. To Kagaku. Ryoho., 18, pp. 1013-1019Rocha-Lima, C.M., Herndon III, J.E., Lee, M.E., Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902 (2007) Ann. Oncol., 18, pp. 331-337Masuda, N., Fukuoka, M., Kusunoki, Y., CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer (1992) J. Clin. Oncol., 10, pp. 1225-1229Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Saijo, N., Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer (2002) New England Journal of Medicine, 346 (2), pp. 85-91. , DOI 10.1056/NEJMoa003034Hanna, N., Bunn Jr., P.A., Langer, C., Einhorn, L., Guthrie Jr., T., Beck, T., Ansari, R., Sandler, A., Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lime cancer (2006) Journal of Clinical Oncology, 24 (13), pp. 2038-2043. , DOI 10.1200/JCO.2005.04.8595Hermes, A., Bergman, B., Bremnes, R., Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial (2008) J. Clin. Oncol., 26, pp. 4261-4267Sørensen, M., Felip, E., ESMO guidelines working group small-cell lung cancer: ESMO clinical recommendations for diagnosis treatment and follow-up (2008) Ann. Oncol., pp. ii41-ii42Kalemkerian, G.P., Akerley, W., Downey, R.J., Ettinger, D.S., Fossella, F., Grecula, J.C., Jahan, T., Williams Jr., C.C., Small cell lung cancer (2008) JNCCN Journal of the National Comprehensive Cancer Network, 6 (3), pp. 294-314Eckardt, J.R., Von Pawel, J., Papai, Z., Tomova, A., Tzekova, V., Crofts, T.E., Brannon, S., Ross, G., Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer (2006) Journal of Clinical Oncology, 24 (13), pp. 2044-2051. , DOI 10.1200/JCO.2005.03.3332Moher, D., Cook, D.J., Eastwood, S., Improving the quality of reports of meta-analyses of randomised controlled trials: The quorom statement quality of reporting of meta-analyses (1999) Lancet, 354, pp. 1896-1900Parmar, M.K.B., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998) Statistics in Medicine, 17 (24), pp. 2815-2834. , DOI 10.1002/(SICI)1097-0258(19981230)17:243.0. CO;2-8Tierney, J.F., Stewart, L.A., Ghersi, D., Burdett, S., Sydes, M.R., Practical methods for incorporating summary time-to-event data into meta-analysis (2007) Trials, 8, p. 16. , DOI 10.1186/1745-6215-8-16Sterne, J.A.C., Egger, M., Smith, G.D., Investigating and dealing with publication and other biases (2001) Systematic Reviews in Health Care: Metaanalysis in Context, pp. 189-210. , In M Egger, GD Smith, DG Altman (Eds 2nd Ed. London: BMJ Publication GroupDerSimonian, R., Laird, N., Meta-analysis in clinical trials (1986) Controlled Clinical Trials, 7 (3), pp. 177-188. , DOI 10.1016/0197-2456(86)90046-2Higgins, J.P., Thompson, S.G., Deeks, J.J., Measuring inconsistency in meta-analyses (2003) BMJ, 327, pp. 557-560Seiter, K., Toxicity of the topoisomerase I inhibitors (2005) Expert Opin. Drug. Saf., 4, pp. 45-53Hartmann, J.T., Lipp, H.P., Camptothecin and podophyllotoxin derivatives: Inhibitors of topoisomerase I and II-mechanisms of action pharmacokinetics and toxicity profile (2006) Drug. Saf., 29, pp. 209-230Pan, D., Hou, M., Li, H., Yu, P., Liu, J., Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: A randomized clinical trial (2006) Chinese Journal of Lung Cancer, 9 (5), pp. 443-446Heigener, D.F., Freitag, L., Eschbach, C., Topotecan/cisplatin TP compared to cisplatin/etoposide PE for patients with extensive diseasesmall cell lung cancer ED-SCLC: Final results of a randomised phase III trial (2008) J. Clin. Oncol., 26. , bstract 7513Zhang, S., Wang, J., Wang, Q., Zhang, H., Hu, F., Yang, X., Fan, X., Li, Xi., A randomized study comparing topotecan plus cisplatin versus etoposide plus carboplatin for previously untreated small cell lung cancer (2007) Chinese Journal of Lung Cancer, 10 (2), pp. 144-147Schmittel, A.H., Sebastian, M., Fischer Von Weikersthal, L., Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial (2009) J. Clin. Oncol., 27. , Abstract 8029Natale, R.B., Lara, P.N., Chansky, K., S0124: A randomized phase III trial comparing irinotecan/cisplatin IP with etoposide/cisplatin EP in patients pts with previously untreated extensive stage small cell lung cancer E-SCLC (2008) J. Clin. Oncol., 26. , Abstract 7512Eckardt, J.R., Von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Ross, G., Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer (2007) Journal of Clinical Oncology, 25 (15), pp. 2086-2092. , DOI 10.1200/JCO.2006.08.3998Ardizzoni, A., Manegold, C., Debruyne, C., Gaafar, R., Buchholz, E., Smit, E.F., Lianes, P., Giaccone, G., European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer (2003) Clinical Cancer Research, 9 (I1), pp. 143-150Naka, N., Kawahara, M., Okishio, K., Hosoe, S., Ogawara, M., Atagi, S., Takemoto, Y., Furuse, K., Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer (2002) Lung Cancer, 37 (3), pp. 319-323. , DOI 10.1016/S0169-5002(02)00073-9, PII S0169500202000739Hirose, T., Horichi, N., Ohmori, T., Ogura, K., Hosaka, T., Ando, K., Ishida, H., Adachi, M., Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer (2003) Lung Cancer, 40 (3), pp. 333-338. , DOI 10.1016/S0169-5002(03)00075-8Takigawa, N., Fujiwara, K., Ueoka, H., Kiura, K., Tabata, M., Hiraki, A., Shibayama, T., Harada, M., Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: A phase II study (2003) Anticancer Research, 23 (B1), pp. 557-560Ioannidis, J.P., Interpretation of tests of heterogeneity and bias in metaanalysis (2008) J. Eval. Clin. Pract., 14, pp. 951-957Hande, K., Messenger, M., Wagner, J., Krozely, M., Kaul, S., Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration (1999) Clinical Cancer Research, 5 (10), pp. 2742-2747Hande, K.R., Krozely, M.G., Greco, F.A., Bioavailability of low-dose oral etoposide (1993) J. Clin. Oncol., 11, pp. 374-377Hotta, K., Kiura, K., Fujiwara, Y., Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer (2009) Ann. Oncol., 20, pp. 829-834Yao, N., Jiang, L., Yang, K., Irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive stage small cell lung cancer: A systematic review (2009) Chin. J. Lung. Cancer, 12, pp. 884-88

Use of emergency contraception in higher education students

The use of emergency contraception, used by women after sexual intercourse to avoid the unintended pregnancy, has been increasing in last decades. The present study aimed to characterize the contraceptives behaviors, with emphasis to emergency contraception, in higher education female students. Using a cross-sectional study, a questionnaire-based study was targeted to 130 students of the Polytechnic Institute of Bragança, with ages between 18 and 36 old. From these students, 75% were sexually active, with the majority of them using contraceptive methods during intercourse. Usually, contraceptive methods comprised masculine condom (35.4%), oral hormonal contraception (14.6%) or both methods (18.5%). Moreover, the use of emergency contraception was assumed by 23% of these students, with one fifth of them using this method for more than once. Thought the analysis of variables, it was found that there is a relationship between age and the start of sexual activity, the use of contraceptive methods during intercourse, and also in between age of the 1st intercourse and the usage of emergency contraceptive methods. The high prevalence of emergency contraception use in these students indicated the trivialization of this type of oral contraception. Them, it is crucial to further disclosure and provision the preventive contraceptive methods once young population is not still aware of their benefits and excessively resort from emergence contraceptive methods

Acupuncture For Cancer Patients Undergoing Chemotherapy In A Brazilian Hospital-an Exploratory Study

Introduction: Integrative Oncology when combined with conventional care can be effective and reduce adverse symptoms of cancer and its treatment. The purpose of this exploratory study was to explore whether individualized acupuncture given to cancer patients at a Brazilian hospital improved symptoms and wellbeing. Methods: This exploratory study was carried out between May 2012 and January 2013. Data from twenty patients who received 8 weekly acupuncture sessions were compared before and after their treatment and also with data from 9 patients who did not receive acupuncture, who acted as comparison group. An adapted version of the MYMOP was used to identify patients' self-reported symptoms and perceptions of wellbeing. Results: After completing the acupuncture sessions with the intervention group, 17 patients reported feeling significantly better (. p>. .0001), one felt worse, one reported no change and one could not be evaluated because he was asymptomatic. Of the comparison group five patients reported feeling better and four felt worse, results were not significantly different. The Student t test was used to compare differences between the acupuncture and comparison group. The results for the intervention group achieved statistically significant changes (. p value. =. 0.016), compared to the comparison group. Conclusion: The acupuncture practice delivered as part of the integrative care in oncology produced clinically and statistically significant changes for the majority of the patients undergoing cancer treatment, resulting in improvements in patients' self reported wellbeing.712328integrative health: what's in a name? This publication is not copyrighted and is in the public domain. NCCAM Pub no.: D347. Date Created, , http://nccam.nih.gov/health/whatiscam, October 2008. Last Updated: July 2014, available at 〈〉 [access 18 Jun 2013]Deng, G.E., Cassileth, B.R., Cohen, L., Gubili, J., Johnstone, P.A.S., Kumar, N., Integrative oncology practice guidelines (2007) J Soc Integr Oncol, 5 (2), pp. 65-68Deng, G.E., Frenkel, M., Cohen, L., Cassileth, B.R., Abrams, D.I., Capodice, J.L., Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals (2009) J Soc Integr Oncol, 7 (3), pp. 85-120Siegel, P., Barros, N.F., Por que as pesquisas em Oncologia Integrativa são importantes? (2013) Rev Bras Cancerol, 59 (2), pp. 249-253. , [article in Portuguese]Quispe-Cabanillas, J.G., Damasceno, A., von Glehn, F., Brandão, C.O., Damasceno, B.P., Silveira, W.D., Impact of eletroacupuncture on quality of life for patients with relapsing-remitting multiple sclerosis under treatment with immunomodulators: a randomized study (2012) BMC Complement Altern Med, 12, p. 209Nishijo, K., Mori, H., Scientific approach for acupuncture (1995) J Jpn Soc Acupunct, 45 (3), pp. 177-191Tanaka, T.H., Possibilities for optimizing acupuncture treatment results through synchronization with somatic state: an examination of autonomic response to superficial needling during exhalation (1996) Am J Acupunct, 24 (4), pp. 233-239Cohen, A.J., Menter, A., Hale, L., Acupuncture: role in comprehensive cancer care-a primer for the oncologist and review of the literature (2005) Integr Cancer Ther, 4 (2), pp. 131-143. , JunArnberger, M., Stadelmann, K., Alischer, P., Ponert, R., Melber, A., Greif, R., Monitoring of neuromuscular blockade at the P6 acupuncture point reduces the incidence of postoperative nausea and vomiting (2007) Anesthesiology, 107 (6), pp. 903-908. , DecGreen, J.P., Lynn, S.J., Montgomery, G.H., Gender-related differences in hypnosis-based treatments for smoking: a follow-up meta-analysis (2008) Am J Clin Hypn, 50 (3), pp. 259-271. , JanBlock, K.I., (2009) Life over cancer, , Bantam Dell, New York, NYZhao, H., Liu, J.P., Liu, Z., Peng, W., Acupuncture for chronic constipation (Protocol for a Cochrane Review) (2014) The Cochrane Library, (9). , http://cochrane.bvsalud.org/cochrane/show.php?db=protocols&mfn=&id=CD004117&lang=&dblang=&lib=COC&print=yes, Firstly published in 2003 issue 2, Available at: [access 26 may 2014](2012) Head and neck cancer: good old acupuncture. [No authors listed]. Nat Rev Clin Oncol, 9. , 188published online 21 Feb 2011Meng, Z., Kay Garcia, M., Hu, C., Chiang, J., Chambers, M., Rosenthal, D.I., Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma (2012) Eur J Cancer, 48 (11), pp. 1692-1699. , JanJohnstone, P.A., Acupuncture as cancer symptom therapy: what a difference a decade makes (2011) J Acupunct Meridian Stud, 4 (4), pp. 209-213. , DecEzzo, J., Vickers, A., Richardson, M.A., Allen, C., Dibble, S.L., Issell, B., Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting (2005) J Clin Oncol, 23 (28), pp. 7188-7198Fu, J., Meng, Z.Q., Chen, Z., Peng, H.T., Liu, L.M., Clinical observation on electric stimulation of Yongquan (Kl 1) for prevention of nausea and vomiting induced by Cisplatin (2006) Zhongguo Zhen Jiu, 26 (4), pp. 250-252Tonezzer, T., Tagliaferro, J., Cocco, M., Marx, A., Uso da estimulação elétrica nervosa transcutânea aplicado ao ponto de acupuntura PC6 para redução dos sintomas de náusea e vÔmitos associados à quimioterapia antineoplásica (2012) Rev Bras Cancerol, 58 (1), pp. 7-14. , [article in Portuguese](2002) Traditional medicine strategy 2002-2005, , WHO, Geneva(2006) Política Nacional de Práticas Integrativas e Complementares, , Ministério da Saúde, Brasília (DF), [article in Portuguese]Facina, T., Estimativa 2012 - Incidência de Câncer no Brasil (2011) Rev Bras Cancerol, 57 (4), p. 557. , [article in Portuguese]Kleinman, A., (1988) The illness narratives: suffering, healing and the human condition, , Basic Books, New York, NYhttp://www.bris.ac.uk/primaryhealthcare/resources/mymop/, University of Bristol, available at 〈〉 [access 13 may 2013]Peters, D., Chaitow, L., Harris, G., Morrison, S., (2002) Integrating complementary therapies in primary care. A practical guide for health professionals, , Churchhill Livingstone, LondonDing, L., (1970) Acupuncture, meridian theory and acupuncture points, , Foreign Languages Press, BeijingYu-Lin, L., Chun-Yang, C., Hammes, M., Kolster, B.C., (2012) Atlas Gráfico de Acupuntura-Seirin, , H.F. Ullmann, Potsdam, [article in Portuguese]Faria Mota, D.D.C., Mattos Pime, C.A., Fadiga em pacientes com câncer avançado: conceito, avaliação e intervenção (2002) Rev Bras Cancerol, 48 (4), pp. 577-583. , [article in Portuguese]Campos, M.P.O., Hassan, B.J., Rachel Riechelmann, R., del Giglio, A., Fadiga relacionada ao câncer: uma revisão (2011) Rev. Assoc. Med. Bras, 57 (2), pp. 211-219. , [article in Portuguese]D'Alessandro, E., Evaluation of acupuncture for cancer symptoms in a cancer institute in Brazil (2013) Acupunct Med, 31 (1), pp. 23-26Hull, S.K., Page, C.P., Skinner, B.D., Linville, J.C., Coeytaux, R.R., Exploring outcomes associated with acupuncture (2006) J Altern Complement Med, 12, pp. 247-254Paterson, C., Vindigni, D., Polus, B., Browell, T., Edgecombe, G., Evaluating a massage therapy training and treatment programme in a remote Aboriginal community: methods and preliminary findings (2008) Complement Ther Clin Pract, 14, pp. 158-167De Valois, B.A., Young, T.E., Melsome, E., Assessing the feasibility of using acupuncture and moxibustion to improve quality of life for cancer survivors with upper body lymphoedema (2012) Eur J Oncol Nurs, 16 (3), pp. 301-309. , JulGuyatt, G.H., Juniper, E.F., Walter, S., Griffith, L., Goldstein, R.S., Interpreting treatment effects in randomised trials (1998) BMJ, 316 (7132), pp. 690-693Barros, N.F., Siegel, P., Moura, S.M., Cavalari, T.A., Silva, L.G., Furlanetti, M.R., Yoga e promoção da saúde. Ciênc. saúde coletiva [serial on the Internet] (2014), 19 (4), pp. 1305-1314. , http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232014000401305&lng=en, Apr [cited 2014 Nov 18]Available from: [article in Portuguese

Increased risk for acute lymphoblastic leukemia in children with cytochrome P450 A1(CYP1A1)- and NAD(P)H: quinone oxidoreductase 1 (NQO1)-inherited gene variants

Sem informação124, n.3, p. 2010318218

Comparison of blood neoangiogenesis and lymphatic vascularization in colorectal adenomas from patients with and without concomitant colorectal cancer

Blood and lymphatic vessel proliferation is essential for tumor growth and progression. Most colorectal carcinomas develop from adenomas (adenoma-carcinoma sequence) in a process due to accumulation of molecular genetic alterations. About 5% of adenomatous polyps are expected to become malignant, but data on the differential angiogenic patterns of these lesions in patients with and without concomitant cancer are missing. The aim of the present study is to compare the angiogenic and lymphatic patterns of adenomatous polyps from patients with and without sporadic cancer. Thirty adenomatous polyps (15 from patients with another principal malignant lesion, and 15 from patients without cancer) were submitted to immunohistochemical staining for CD105 (marker for neoangiogenesis) and D2-40 (marker for lymphatic endothelium). Microvessel density and total vascular area were determined by computer image analysis to quantify the immunostained and total areas, and to assess the number of microvessels. Adenomas from patients with carcinoma showed significantly higher values of total vascular area determined by immunostaining for CD105 (cutoff value = 4386 µm²; P = 0.019) and of lymphatic microvessel density determined by immunostaining with D2-40 (cutoff value = 11.5; P = 0.041) when compared with those from patients without cancer. The present data indicate a significant increase in blood microvascular area and in lymphatic microvascular counts in adenomas removed from patients with cancer